---
schema_version: "secwatch.filing_event.v1"
accession: "0001178670-25-000076"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2025-06-18T23:59:59+00:00"
generated_at: "2026-05-19T02:31:43.013229+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Alnylam promotes Pushkal Garg to Chief R&D Officer; merges R&D functions

## Summary
- Pushkal Garg appointed EVP, Chief Research and Development Officer to lead integrated R&D organization.
- Kevin Fitzgerald's role expanded to include external innovation; receives one-time RSU grant of $2.5M.
- Garg's base salary set at $825,000 with STI target of 65% of base; LTI target to be determined.
- Fitzgerald's STI target increased to 60% of base salary.
- Alnylam targets delivering RNAi therapeutics to all major tissues by 2030.

## SEC filing metadata
- accession: 0001178670-25-000076
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2025-06-18T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000117867025000076/0001178670-25-000076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000117867025000076/alny-20250612.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178670-25-000076
- JSON: https://secwatch.observer/filing/0001178670-25-000076.json
- Plain text: https://secwatch.observer/filing/0001178670-25-000076.txt

## Key facts
- Executive change
  Pushkal Garg was appointed as Executive Vice President, Chief Research and Development Officer at ALNYLAM PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Executive Vice President, Chief Research and Development Officer
  source text: the Committee approved (i) the appointment of Pushkal Garg, M.D., the Company’s current Chief Medical Officer, Executive Vice President, Development and Medical Affairs, to the position of Executive Vice President, Chief Research and Development Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000117867025000076/0001178670-25-000076-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.